Showing posts with label Reolysin. Show all posts
Showing posts with label Reolysin. Show all posts
Friday, January 21, 2011
Monday, September 13, 2010
media: Novel Study Using Reoviruses Against Ovarian Cancer Pushes Forward
Calgary-based Oncolytics Biotech Inc. recently announced that the Gynecologic Oncology Group (GOG) intends to conduct a randomized Phase II trial of weekly paclitaxel versus weekly paclitaxel with REOLYSIN® in patients with persistent or recurrent ovarian, fallopian tube or primary peritoneal cancer (GOG186H).
add your opinions
clinical trial
,
GOG
,
GOG186H
,
Oncolytic biotech
,
Reolysin
Monday, September 06, 2010
Oncolytics Biotech(R) Inc. Announces Randomized Phase II Ovarian Cancer Study to be Conducted by the Gynecologic Oncology Group and Sponsored by the National Cancer Institute
Press Release: Sept. 2 /PRNewswire-FirstCall/ - Oncolytics Biotech Inc. ("Oncolytics") (TSX:ONC, NASDAQ: ONCY) announced today that the Gynecologic Oncology Group (GOG) intends to conduct a randomized Phase II trial of weekly paclitaxel versus weekly paclitaxel with REOLYSIN(R) in patients with persistent or recurrent, ovarian, fallopian tube or primary peritoneal cancer (GOG186H). The study has been approved and will be sponsored by the Cancer Therapy Evaluation Program, Division of Cancer Treatment and Diagnosis, U.S. National Cancer Institute (NCI), which is part of the National Institutes of Health, under its Clinical Trials Agreement with Oncolytics. Oncolytics will provide clinical supplies of REOLYSIN for this study.......Information on the study will be available at www.clinicaltrials.gov.
add your opinions
clinical trial
,
Paclitaxel
,
phase 11
,
Reolysin
,
Taxol
Subscribe to:
Posts
(
Atom
)